P4‐212: EXPECT (EXelon Patch EffeCtiveness Trial): Effectiveness and tolerability of transdermal rivastigmin in daily practice

Abstract

in a linear manner with increasing dose [AUC t (mg-h/mL; mean 6 SD) for 0.15 mg/kg: 1260 6 254, 0.5 mg/kg: 4264 6 462, 1.0 mg/kg: 7818 6 652, 2.0 mg/kg: 15313 6 8478]. Mean t 1/2 ranged from 15.0 to 28.1 days. Bapineuzumab clearance was similar across dose groups (range: 0.12 -0.17 mL/h/kg). Plasma Aß x-40 levels increased with increasing doses of bapineuzumab (Fig. 2). No anti-bapineuzumab antibodies were found in any of the samples tested. Conclusions: Bapineuzumab was generally safe and well tolerated at doses of 0.15 mg/kg, 0.5 mg/kg, 1.0 mg/kg, and 2.0 mg/kg in Japanese patients with mild to moderate AD. The pharmacokinetic profile of bapineuzumab in Japanese patients is consistent with that observed in other studies with non-Japanese patients.